Tenderwize
Retour à la recherche

Non-exclusive rebate agreement for Ciclesonid

GWQ ServicePlus AG·Düsseldorf, Germany·Deadline Nov 10, 2027 · 439 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V ab dem 01.06.2026

52/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

52 / 100

Complexité

58 / 100

Facteurs de risque

The structured data marks the procedure as open, while the notice text states the GWQ believes the arrangement falls ou...

The structured data deadline is 2027-11-10T09:00:00Z, while the XML notice shows an end date/time of 2027-11-10 10:00:0...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Dec 2027
  • Non-exclusive rebate agreements for pharmaceutical products under § 130a(8) SGB V.
  • Active substance: Ciclesonid.
Afficher le résumé complet

This is a German supplies notice for non-exclusive pharmaceutical rebate agreements for the active substance Ciclesonid, starting 01.06.2026. The procedure is described as an open procedure in the structured data, but the notice text also states the GWQ considers it outside cartel procurement law due to open accession for all interested companies. Submission is postal only; electronic submission is not allowed. No contract value is provided. Procurement documents are available on the buyer portal, but only the TED XML notice text was provided for analysis.

Risques

The structured data marks the procedure as open, while the notice text states the GWQ believes the arrangement falls ou...

The structured data deadline is 2027-11-10T09:00:00Z, while the XML notice shows an end date/time of 2027-11-10 10:00:0...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Signed contract in duplicate.
  • Proof of marketing authorization via extract from the public part of the AMIce database.

Administrative

  • Signed self-declaration (Annex 3).

Acheteur

Localisation

Düsseldorf, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE258895210

Activité

Health

Lots (1)

LOT-0000

Non-exclusive rebate agreement for Ciclesonid

Lot for a non-exclusive rebate agreement concerning the active substance Ciclesonid. The contract is open to all interested companies on equal terms during the contract period (accession model). The lot concerns pharmaceutical supplies in Germany and appears to be a transitional arrangement until exclusive contracts start.

SuppliesEU fundedElectronic submission

Localisation

DEA11, Germany

Durée

May 2026 - Dec 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Nov 10, 2027

Détails de la procédure

Date de publication
06 May 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
314119-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30